

1 Evaluation of sample collection and transport strategies to enhance yield, accessibility, and
2 biosafety of COVID-19 RT-PCR testing

3
4 Padmapriya Banada^a, David Elson^{a*}, Naranjargal Daivaa^{a*}, Claire Park^a, Samuel Desind^a, Ibsen
5 Montalvan^b, Robert Kwiatkowski^c, Soumitesh Chakravorty^{a,c}, David Alland^{a,b#}, Yingda L. Xie^{a,b#}

6 ^aPublic Health Research Institute; Center for Emerging Pathogens, Rutgers New Jersey Medical
7 School, 185 S. Orange Av, Newark, NJ 07103; ^b University Hospital, 150 Bergen St, Newark, NJ
8 07103, ^c Cepheid, Sunnyvale, CA.

9 Running Head: Enhanced sampling for COVID-19 RT-PCR

10 Key words: Saliva, Nasal, Oral, eNAT, Inactivation

11 * Contributed equally

12 #Equal contribution corresponding authors: Address correspondence to Yingda Xie
13 ylx1@njms.rutgers.edu and David Alland allandda@njms.rutgers.edu

14
15 Conflicts of Interest: DA receives research support and royalty payments from Cepheid. RK and
16 SC are employed by Cepheid.

17
18
19
20

21 **ABSTRACT**

22 Sensitive, accessible, and biosafe sampling methods for COVID-19 reverse-transcriptase
23 polymerase chain reaction (RT-PCR) assays are needed for frequent and widespread testing. We
24 systematically evaluated diagnostic yield across different sample collection and transport
25 workflows, including the incorporation of a viral inactivation buffer. We prospectively collected
26 nasal swabs, oral swabs, and saliva, from 52 COVID-19 RT-PCR-confirmed patients, and
27 nasopharyngeal (NP) swabs from 37 patients. Nasal and oral swabs were placed in both viral
28 transport media (VTM) and eNAT™, a sterilizing transport buffer, prior to testing with the Xpert
29 Xpress SARS-CoV-2 (Xpert) test. The sensitivity of each sampling strategy was compared using
30 a composite positive standard. Overall, swab specimens collected in eNAT showed superior
31 sensitivity compared to swabs in VTM (70% vs 57%, $P=0.0022$). Direct saliva 90.5%, (95% CI:
32 82%, 95%), followed by NP swabs in VTM and saliva in eNAT, was significantly more sensitive
33 than nasal swabs in VTM (50%, $P<0.001$) or eNAT (67.8%, $P=0.0012$) and oral swabs in VTM
34 (50%, $P<0.0001$) or eNAT (56%, $P<0.0001$). Saliva and use of eNAT buffer each increased
35 detection of SARS-CoV-2 with the Xpert test; however, no single sample matrix identified all
36 positive cases.

37

38

39

40 INTRODUCTION

41 Accurate, efficient, and biosafe detection of SARS-CoV-2 in both symptomatic and asymptomatic
42 individuals with active COVID-19 infection is an essential public health strategy for preventing
43 transmission and controlling the COVID-19 pandemic. Although nasopharyngeal (NP) swabs are
44 a preferred specimen type, the invasiveness of this procedure, potential for variable collection
45 quality, need for supervised collection with biohazard risks have hindered the scalability of this
46 testing method¹⁻⁴. Rather, there has been progress in establishing utility of non-invasive sampling
47 methods that use saliva⁵⁻⁷ or self-collected nasal or oral swabs^{8,9} which can enable broader testing
48 of at-risk populations and decrease exposure risk to healthcare workers¹⁰. When combined with
49 self-testing, wider implementation of rapid, CLIA-waived COVID-19 assays^{11,12} could
50 dramatically increase public access to tests for SARS-COV-2 infection by expanding testing in at-
51 risk locations including school and the workplace. However, the feasibility of scaling these non-
52 invasive samples for widespread testing outside of carefully controlled environments remains
53 limited by the operational and biosafety challenges.

54 Our group has recently demonstrated that a guanidine-thiocyanate transport buffer (eNAT™,
55 Copan diagnostics Murrieta, CA) leads to viral inactivation, with at least 5-log reduction in viable
56 SARS-COV-2, and stabilization of viral RNA in a sample¹³. With the premise that eNAT could
57 optimize testing yield while simplifying sample transport and handling, we evaluated and
58 compared the yield of eNAT versus standard transport media, across different non-invasive
59 samples, using the Cepheid Xpert Xpress SARS-COV-2 test ('Xpert'). Xpert is a FDA- EUA
60 approved rapid, integrated, cartridge-based RT-PCR test that can be run on widely existing
61 GeneXpert instruments used in over 130 countries. To our knowledge, this is the first study to
62 demonstrate the use of a viral inactivating buffer across various non-invasive samples in a point-

63 of-care test to deliver a complete and scalable work flow for biosafe handling and testing of
64 COVID samples.

65

66 **MATERIALS AND METHODS**

67 **Study population and sample collection.** To collect SARS-CoV-2 positive samples from
68 COVID-19 PCR confirmed participants, we conducted a sub-study to an observational cohort
69 study of COVID-19 patients at University Hospital (UH) affiliated with the Rutgers New Jersey
70 Medical School in Newark, NJ, USA. This study was approved by the Rutgers Institutional Review
71 Board for human subject research (Rutgers IRB # Pro2020001138). Eligible patients included
72 adults (age ≥ 18) who tested SARS-CoV-2 PCR-positive by the in-hospital NP swab PCR tests
73 (most commonly Simplexa COVID-19 Direct EUA (Diasorin Molecular LLC, Cypress, CA)).
74 Patients that could not or did not consent, were pregnant or breastfeeding, prisoners, or who were
75 unable to provide any respiratory specimens were excluded. Trained study personnel collected 1
76 NP swab (baseline only), 2 oral swabs, 2 nasal swabs, and a saliva sample from all participants
77 who consented to all sample types. A subset of participants being evaluated for hospital outcomes
78 in the parent study continued to be sampled longitudinally by oral swabs, nasal swabs, and saliva
79 every 2-3 days until discharge. All swab types were immediately placed into 3mL of sterile
80 Universal Viral Transport Medium (VTM; Labscoop, Little Rock, AR) whereas a second nasal
81 and oral swab was collected and immediately placed into 3mL of eNAT (COPAN Diagnostics,
82 Murrieta, CA, USA). A thinner nylon tip swab designed for nasopharyngeal (NP) sampling was
83 used to obtain the NP swab (baseline only), and a thicker nylon tip swab designed for oral and
84 nasal samples (Copan diagnostic, Murrieta, CA) was used for these sample types. NP swab
85 collection was performed in accordance with CDC guidelines¹⁴; oral swab collection was

86 performed by swabbing both buccal surfaces and tongue with an alternating order of collection for
87 each media; nasal (anterior nares) swab collection was performed by rotating the swab 1 cm inside
88 the nostril for 10-15 seconds, alternating nostrils for each media. Additionally, participants were
89 instructed to self-collect a posterior saliva sample by clearing the back of their throat, then
90 collecting 4 mL of saliva into a marked, empty, sterile wide-mouth cup (though any volume over
91 0.5 mL was accepted). All specimens were transported at room temperature and stored in a 2-4°C
92 prior to testing, which occurred within 48 hours of sample collection.

93 **Testing by Xpert Xpress SARS-Cov-2 ('Xpert')**. NP, nasal, and oral swabs were tested by
94 adding 300µl of the sample (either in VTM or eNAT) directly to the Xpert SARS-Cov-2 test
95 cartridges and the test was run in the GeneXpert system as per the manufacturer's instructions.
96 The saliva sample was tested using three different methods. First, 300µl of the saliva sample was
97 directly added into the Xpert test cartridge ("saliva direct" sample). Additionally, the same saliva
98 sample was swabbed with two separate swabs (thicker nylon tip swabs) for 10 twirls followed by
99 incubating each swab in the saliva for ~10-20 seconds ("saliva swab" sample). Each saliva swab
100 sample was then transferred into test tubes containing 3mls of either VTM or 2 ml of eNAT buffer
101 and mixed well. From each of these mixtures, 300µl were added directly to the sample chamber
102 of Xpert cartridges. Saliva samples <300 µl were tested only by swabbing in eNAT and VTM.
103 We also compared saliva samples directly diluted in 1:1, 1:2 and 1:4 ratios of saliva to eNAT. A
104 minimum volume of 700µl of saliva was needed to test all saliva processing methods: 'saliva
105 direct', saliva swab in eNAT and all three dilutions. For saliva samples with volumes less than
106 700µl, we prioritized saliva direct and saliva swab testing. Out of the 44-saliva direct positive
107 samples tested with eNAT ratios, 1:1 dilution was not performed for one saliva sample due to
108 insufficient volume. One each of the sample types had an error either due to pressure aborts (Error

109 2008) or probe check error (Error 5017) or instrument hardware error (Error 2025) and were not
110 repeat tested. The saliva:eNAT mixtures were then tested using the GeneXpert system by adding
111 300µl of the mixture to the Xpert SARS-CoV-2 test cartridge. The effect on the assay inhibition,
112 N2 gene cycle threshold (Ct), percent positive rate and cartridge pressure values were evaluated.

113 **Definitions.** We compared samples that were collected contemporaneously (sample comparison
114 set) and applied a composite SARS-CoV-2 positive reference standard, defined as at least one
115 sample type being positive in the sample comparison set. We did not compare sample sets in which
116 no samples were positive, as we reasoned that the PCR-negative samples from these individuals
117 could not be considered false negative due to biologic variability in sampling over time, but they
118 were also not suitable as true negative comparators due to known COVID status of these
119 individuals. To confirm the discordancy that negative comparison sets was not due to difference
120 in the in-hospital versus Xpert PCR tests, we obtained leftover media from positive NP swabs of
121 a random subset of six participants. We then tested this archived sample as validation samples on
122 Xpert. Xpert correctly detected SARS-CoV-2 in all six of these archived samples.

123 **Statistical analyses.** Standard statistical analyses (average, standard deviation, and t-test) and
124 proportion of positive tests by each sampling method were compared by Chi-square, t-test or z-
125 test as appropriate, using Microsoft Excel 365 for Windows, GraphPad Prism version 8 or online
126 software (http://vassarstats.net/propdiff_ind.html). Scatter plots for Ct values showing the mean
127 and SD were included for the positive samples.

128

129 **RESULTS**

130 **Participant enrollment and characteristics.** Between June 12th, 2020 and October 23rd, 2020,
131 70 subjects were enrolled into the study (Figure 1). From these 70 enrollees, a total of 116 sample
132 comparison sets were collected - 70 at baseline and 46 at follow-up time-points. Of note, some
133 participants consented to all sample types except for NP swabs. Of the 116 comparison sets, 84
134 sample sets from 52 participants were complete with all specimen types and had at least one sample
135 positive (by the composite reference standard) and were thus included in the sample comparison
136 analysis (Fig. 1). Characteristics of the 52 participants in the analysis population (participants with
137 at least one study sample positive for SARS-CoV-2) are shown in Table 1 and characteristics of
138 the 13 participants with all negative samples are shown in Supplementary Table S1. Among the
139 52 participants in the analysis population, 41 (79%) had symptoms potentially consistent with
140 COVID whereas 11 (21%) of these participants presented to the hospital for non-COVID
141 indications, had no respiratory symptoms, and were incidentally found to be COVID-positive.
142 Average participant age was 55, 37% were female, and the most common comorbidities were
143 hypertension and diabetes.

144 On average, the baseline collection took place 2 days after the last positive in-hospital NP swab
145 PCR test for participants in the analysis group, and 3 days for participants with no positive samples.
146 The biologic variability of PCR positivity from samples collected several days apart was evident
147 in the discordancy of longitudinal in-hospital NP swab PCR testing results even when the same
148 test was used. Nineteen (38%) of the 52 participants in the analysis group had at least one
149 subsequent negative in-hospital NP swab PCR test during their hospital admission (Table 1).
150 Additionally, we validated 100% agreement of the in-house test with Xpert (all the original
151 samples were Xpert positive) from the original left-over positive NP swab specimen of 6
152 participants. These observations support that positive-negative discordancy across time was likely

153 biologic or sampling variability and unlikely due to discordancy between the in-hospital and
154 Cepheid tests, and is consistent with previous comparative performance of Xpert Xpress SARS-
155 CoV-2 with other SARS-CoV-2 RT-PCR platforms ^{11, 15, 16}.

156 **Comparative testing of different respiratory specimens in Xpert Xpress SARS-COV-2.** A
157 total of 84 sample comparison sets from 52 patients were included in the sample comparison
158 analysis based on the composite reference, where at least one specimen in the comparison set was
159 positive. Seventeen of these patients had follow-up samples collected on alternative days during
160 their hospital stay. Thus, a total of 84 sets of all specimen types were included in the analysis
161 except for NP swabs, which were only collected from 51 completed baseline collections. Of the
162 51 completed baseline collections, 14 participants declined NP swab, leaving a total of 37 sample
163 sets that could be analyzed with NP swab.

164 As shown in Fig. 2A, undiluted saliva added directly to the cartridge ('direct saliva') gave the
165 highest detection rate at 90.5% (76/84), followed by NP-VTM (86.5%, 32/37) and saliva in eNAT
166 buffer (84.5%; 71/84), which were significantly higher compared to nasal or oral swabs
167 ($P < 0.0001$). Saliva in VTM (71.4%; 60/84) also performed better than oral swabs in VTM (50%;
168 42/84) or eNAT (58%; 49/84), as well as nasal swabs in VTM (50%; 42/84) or eNAT (67.8%;
169 57/84). We further analyzed N2-gene cycle threshold (Ct) values for all positive samples as shown
170 in Fig. 2B. Average N2 gene Ct values were the earliest for NP-VTM (32 ± 5.4) and saliva direct
171 ($Ct = 34.2 \pm 5.8$) and most delayed for oral-VTM (37.5 ± 4.9). The Ct range difference was
172 statistically significant between saliva direct and oral-VTM ($P < 0.0001$), oral-eNAT ($P = 0.0003$)
173 and saliva-VTM ($P = 0.0026$). However, there was no significant difference of N2-Ct range for NP-
174 VTM ($P = 0.28$), nasal-VTM ($P = 0.09$), nasal-eNAT ($P = 0.82$) and saliva-eNAT ($P = 0.26$) compared
175 to saliva direct (Fig. 2B). There were three negative NP specimens that were detected in saliva,

176 which we observed to have N2 Ct values of 39.4, 40.3 and 36.1 (Supplementary Fig. 1C),
177 indicating below LOD level viral loads ¹⁷ possibly contributing to the discrepancy. Only one of
178 the sample sets was positive by NP swab (Ct=35.4) but negative in saliva direct and both saliva
179 swabs (VTM and eNAT). Overall, we found that saliva performed better or equal to NP swabs in
180 detecting COVID positive patients. Similarly, the samples that were negative by other respiratory
181 specimens (nasal or oral swab) but detected by saliva swab in VTM or eNAT had an overall
182 delayed N2-Ct values of >37, indicating better performance in saliva for samples with low viral
183 load (sub-LoD) or lesser variation in saliva collection.

184 **Influence of transport media on detection across all sample types.** We also evaluated if the
185 composition of different transport media, specifically VTM and eNAT, had any influence on the
186 detection sensitivity. As described, nasal and oral swabs were collected in both VTM and eNAT
187 whereas saliva was collected from patients in an empty sterile cup, then subsequently swabbed and
188 stored in VTM and eNAT. As shown before in Fig. 2A, compared to VTM, eNAT increased the
189 positivity rate by about 20% (40/84 vs 57/84) for nasal swabs (P=0.008), followed by 12% for
190 saliva (60/84 vs 70/84, P=0.065) and 6% for oral swabs (42/84 vs 47/84, P=0.43). When data from
191 all sample types were combined to compare the two media, eNAT offered over 12% advantage
192 (142 vs 174 out of 252 samples) in overall detection rate compared to VTM (P=0.003).

193 **Optimizing the use of eNAT buffer for saliva.** Compared to saliva swabbed into eNAT, direct
194 saliva yielded an overall delayed SPC-Ct values in the Xpert test, indicating possible PCR
195 inhibition and increased (>60 PSI) in-cartridge pressure values (Supplementary Fig. 2B). Saliva
196 diluted into eNAT at a ratio of 1:2 (N=43) yielded the second highest PCR positive rate (97.7%,
197 42/43) after saliva direct (100%, 43/43) (Fig. 3). Dilutions of 1:1 and 1:4 yielded 95% (40/42) and
198 93% (40/43) positive rate, respectively. Saliva swabs in eNAT showed the lowest sensitivity at

199 86% (37/43, $P > 0.05$; Fig. 3A). A sample missed by 1:2 & 1:4 dilutions and another by 1:1 & 1:4
200 dilutions, had delayed N2-Ct values of 44.3 and 41.7 with saliva direct, respectively, indicating the
201 influence of Poisson distribution for viral loads considerably below the limit of detection. Whereas
202 the average N2-Ct values were similar (ca. 33-34) for all saliva conditions tested ($P > 0.05$), the
203 SPC-Ct values were earlier with saliva in eNAT compared to saliva direct (31.25 ± 1.74 , $P < 0.001$,
204 Supplementary Fig. 2C), suggesting that PCR inhibition was mitigated by the addition of eNAT
205 to an appreciable extent.

206 **Operational characteristics of processing saliva in GeneXpert cartridges:** To evaluate saliva
207 processing profiles in the GeneXpert cartridges, we analyzed the sample processing control (SPC)
208 Ct values and in-cartridge pressure values. All respiratory samples collected in either VTM or
209 eNAT did not have any significant difference either with SPC Ct or the max pressure values
210 (Supplementary Fig. 2A and 2B). Saliva direct, the only sample type analyzed as is without
211 dilution, yielded slightly delayed SPC Ct and higher cartridge pressure values with an average of
212 58 ± 13.48 , with one sample aborting the run due to pressure exceeding 100 psi (vs NP-VTM,
213 $P < 0.0001$). However, when the saliva was swabbed and transferred to VTM or eNAT, average
214 pressure values fell to 53.2 ± 6.06 ($P < 0.0001$) and 52.2 ± 5.4 ($P < 0.0001$), respectively. Dilution with
215 eNAT at 1:1, 1:2 and 1:4 ratio reduced the inhibition from saliva direct ($P < 0.0001$) by lowering
216 the average SPC-Ct values by ~2 ct values (Ct 29.1 in 1:2 vs 31.2 in saliva direct). There was no
217 significant difference in maximum in-cartridge pressure values with saliva dilution in eNAT
218 ($P > 0.05$), except for swab in eNAT ($P = 0.02$). These results suggest that particles or mucus present
219 in direct saliva samples can occasionally interfere with assay function, and that swab testing may
220 be considered when these situations occur.

221

222 **DISCUSSION**

223 We found that saliva is an excellent test matrix for the Xpert Xpress SARS-CoV-2 test, providing
224 a sensitivity that is comparable to NP swabs and better than nasal and oral swabs. This finding is
225 consistent with previously published studies using other RT-qPCR modalities ¹⁸⁻²³. Although a
226 handful of previous studies have looked at saliva tested in the Xpert SARS-CoV-2 ^{11, 24, 25}, to our
227 knowledge this study is the first study to comprehensively test multiple non-invasive sampling
228 methods, in the setting of both symptomatic and asymptomatic SARS-COV-2 infection, with and
229 without the use of a sterilizing sample/transport buffer. By applying a composite reference
230 standard for a positive sample, we observed that saliva enhanced the detection of SARS-CoV-2
231 compared all other sampling types. This finding may be largely attributable to more reliable SARS-
232 CoV-2 yield with saliva sampling as opposed to higher variability of swab sampling, consistent
233 with similar observations from other studies ^{1, 5-7}. It is worth noting that noB sample matrix was
234 100% sensitive compared to the composite reference standard. Discordancy between sample
235 matrices was most pronounced in samples that had a delayed cycle threshold indicating low viral
236 load. This suggests that testing with multiple samples and perhaps multiple sample types when
237 clinical suspicion is high may provide the highest sensitivity and negative predictive value for
238 SARS-CoV-2.

239 We additionally found that eNAT, a buffer we have previously determined to be effective at
240 inactivating SARS-CoV-2 in-vitro (Banik et al., submitted), increased the test positivity rates
241 across all sample types compared to VTM (P=0.0032), with a saliva to eNAT ratio of 1:2 being
242 optimal in our sample set. We also found that adding eNAT to saliva possibly mitigates the PCR
243 interference from saliva with lower pressure values and recovery of otherwise delayed SPC Ct
244 values seen with direct saliva. These findings suggest that the application of eNAT as a sample

245 buffer may be advantageous not only in safe handling and transport, but also in improving yield
246 and processing capability on the Cepheid system.

247 There were several limitations in this study. First, there were less contemporaneous NP swabs
248 collected with saliva, thereby reducing the number of direct comparisons between these two
249 sample types, although they were found to be comparable. An underlying reason for this –
250 participants declining NP swab collection due to its discomfort – also demonstrates the real-world
251 limitations that would be magnified with larger scale testing such as in schools or the workplace.
252 Secondly, we added eNAT to saliva in the laboratory, whereas the benefit of eNAT would be to
253 sterilize samples immediately after collection and before transport and test set up. However, this
254 allowed us to evaluate the combination of eNAT and saliva under different conditions and inform
255 optimal design of kits to add eNAT immediately to saliva upon collection. Finally, our participants
256 were patients who had either been admitted to the hospital or seen in the emergency department.
257 This population may not be generalizable to ambulatory individuals who would benefit the most
258 from self-collection. However, we captured a diverse patient group in our cohort including those
259 who were never admitted, as well as patients who were detected by universal screening but
260 reported no COVID symptoms.

261 Altogether, our findings support the use of saliva and eNAT sterilizing buffer to enhance effective,
262 safe, and accessible COVID testing and screening in the many health care systems worldwide
263 already using GeneXpert instruments.

264

265

266

267 Acknowledgements: We thank Dr. Jason H. Yang (Rutgers New Jersey Medical School) for
268 supporting DE's and CP's role in the studies, Cepheid for in-kind donation of cartridges, and
269 Copan for donation of eNAT media and swabs. This study was partially funded by the National
270 Institute of Allergy and Infectious Diseases of the National Institutes of Health under award
271 number R01 AI131617 and Rutgers University Institutional Support.

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286 **References**

- 287 [1] Qian Y, Zeng T, Wang H, Xu M, Chen J, Hu N, Chen D, Liu Y: Safety management of nasopharyngeal
288 specimen collection from suspected cases of coronavirus disease 2019. *Int J Nurs Sci* 2020, 7:153-6.
- 289 [2] Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, Beeman M, Mahmood T, Nze U, Gale BK:
290 SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and
291 commercial response with associated advantages and limitations. *Analytical and Bioanalytical Chemistry*
292 2020.
- 293 [3] Kinloch NN, Ritchie G, Brumme CJ, Dong W, Lawson T, Jones RB, Montaner JSG, Leung V,
294 Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL: Suboptimal Biological Sampling as a Probable
295 Cause of False-Negative COVID-19 Diagnostic Test Results. *The Journal of Infectious Diseases* 2020,
296 222:899-902.
- 297 [4] Surkova E, Nikolayevskyy V, Drobniewski F: False-positive COVID-19 results: hidden problems and
298 costs. *The Lancet Respiratory Medicine*.
- 299 [5] Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Sukswan W,
300 Sungkanuparph S, Phuphuakrat A: Saliva sample as a non-invasive specimen for the diagnosis of
301 coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect* 2020.
- 302 [6] Vaz SN, Santana DS, Netto EM, Pedroso C, Wang WK, Santos FDA, Brites C: Saliva is a reliable, non-
303 invasive specimen for SARS-CoV-2 detection. *Braz J Infect Dis* 2020.
- 304 [7] Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren JL,
305 Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A,
306 Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus
307 S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E,
308 Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS,
309 Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI: Saliva or Nasopharyngeal Swab Specimens
310 for Detection of SARS-CoV-2. *N Engl J Med* 2020, 383:1283-6.
- 311 [8] McCulloch DJ, Kim AE, Wilcox NC, Logue JK, Greninger AL, Englund JA, Chu HY: Comparison of
312 Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for
313 Detection of SARS-CoV-2 Infection. *JAMA Network Open* 2020, 3:e2016382-e.
- 314 [9] Tu Y-P, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta D, Berke EM: Swabs
315 Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. *New England Journal of Medicine*
316 2020, 383:494-6.
- 317 [10] To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung
318 DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY: Consistent Detection of 2019
319 Novel Coronavirus in Saliva. *Clin Infect Dis* 2020, 71:841-3.
- 320 [11] Chen JH, Yip CC, Poon RW, Chan KH, Cheng VC, Hung IF, Chan JF, Yuen KY, To KK: Evaluating the use
321 of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. *Emerg*
322 *Microbes Infect* 2020, 9:1356-9.
- 323 [12] Ravi N, Cortade DL, Ng E, Wang SX: Diagnostics for SARS-CoV-2 detection: A comprehensive review
324 of the FDA-EUA COVID-19 testing landscape. *Biosensors and Bioelectronics* 2020, 165:112454.
- 325 [13] Banik S, Saibire K, Suryavanshi S, Johns G, Chakravorty S, Kwiatkowska R, Alland D, Banada PP:
326 Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR
327 diagnostic assays. *medRxiv* 2021:2021.01.15.21249891.
- 328 [14] CDC: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. 2020.
- 329 [15] Lieberman JA, Pepper G, Naccache SN, Huang ML, Jerome KR, Greninger AL: Comparison of
330 Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical
331 Laboratories. *J Clin Microbiol* 2020, 58.

- 332 [16] Zhen W, Manji R, Smith E, Berry GJ: Comparison of Four Molecular In Vitro Diagnostic Assays for the
333 Detection of SARS-CoV-2 in Nasopharyngeal Specimens. *J Clin Microbiol* 2020, 58.
- 334 [17] Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, Carroll KC, Mostafa H, Davies
335 E, McEwan A, Rakeman JL, Fowler RC, Pawlotsky JM, Fourati S, Banik S, Banada PP, Swaminathan S,
336 Chakravorty S, Kwiatkowski RW, Chu VC, Kop J, Gaur R, Sin MLY, Nguyen D, Singh S, Zhang N, Persing DH:
337 Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. *J Clin Microbiol* 2020, 58.
- 338 [18] Alizargar J, Etemadi Sh M, Aghamohammadi M, Hatefi S: Saliva samples as an alternative for novel
339 coronavirus (COVID-19) diagnosis. *J Formos Med Assoc* 2020, 119:1234-5.
- 340 [19] Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, Ageno W, Gambarini C, Maffioli L, Saverio
341 SD, Gasperina DD, Genoni AP, Premi E, Donati S, Azzolini C, Grandi AM, Dentali F, Tangianu F, Sessa F,
342 Maurino V, Tettamanti L, Siracusa C, Vigezzi A, Monti E, Iori V, Iovino D, Ietto G, Grossi PA, Tagliabue A,
343 Fasano M: Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic
344 accuracy study. *J Infect* 2020, 81:e75-e8.
- 345 [20] Chu AW, Chan WM, Ip JD, Yip CC, Chan JF, Yuen KY, To KK: Evaluation of simple nucleic acid
346 extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during
347 global shortage of extraction kits. *J Clin Virol* 2020, 129:104519.
- 348 [21] Lai CKC, Chen Z, Lui G, Ling L, Li T, Wong MCS, Ng RWY, Tso EYK, Ho T, Fung KSC, Ng ST, Wong BKC,
349 Boon SS, Hui DSC, Chan PKS: Prospective Study Comparing Deep Throat Saliva With Other Respiratory
350 Tract Specimens in the Diagnosis of Novel Coronavirus Disease 2019. *J Infect Dis* 2020, 222:1612-9.
- 351 [22] Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M, Kato K, Imoto Y,
352 Iwata M, Mimura S, Ito T, Tamura K, Kato Y: Clinical Evaluation of Self-Collected Saliva by Quantitative
353 Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal
354 Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin Microbiol* 2020, 58.
- 355 [23] Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM: Self-Collected
356 Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the
357 Molecular Detection of SARS-CoV-2. *J Clin Microbiol* 2020, 58.
- 358 [24] McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K, Cavuoti D: Saliva
359 as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid
360 Xpert Xpress SARS-CoV-2. *J Clin Microbiol* 2020, 58.
- 361 [25] Wong RC, Wong AH, Ho YI, Leung EC, Lai RW: Evaluation on testing of deep throat saliva and lower
362 respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay. *J Clin Virol* 2020, 131:104593.

363

364

365

366

367

368

369

370 Figure Legends.

371

372 Figure 1. Study flowchart.

373

374 Figure 2. Comparative testing of different respiratory specimens using the Xpert Xpress SARS-
375 COV-2 test. (A) Percent positive rate and (B) N2 gene cycle threshold (Ct) values of samples from
376 all participants with at least one SARS-COV-2 positive sample (N=84 for all samples and N=37
377 for NP swab). NP=Nasopharyngeal; VTM=Viral transport medium; eNAT= eNAT™ transport
378 media, Copan diagnostics. ns=not statistically different. **** P<0.0001; ***P<0.001, **P=0.02

379

380 Figure 3. eNAT as a transport media for saliva. Saliva diluted with eNAT at 1:1, 1:2, and 1:4 ratio
381 showing (A) Percent positive rate and (B) N2-Ct values from patient saliva samples tested directly
382 (N=44), as a swab in eNAT (N=44), diluted 1:1 (N=44), 1:2 (N=42), and 1:4 (N=42) in eNAT
383 transport media. ns=not statistically significant.

384

385

386 Table 1. Characteristics of participants in the analysis population (participants with at least one
387 study sample positive for SARS-CoV-2).

	Analysis population (N=52)
Mean Age in years (SD)	55 (15.1)
# of Men (%) # of Women (%)	33 (63%) 19 (37%)
Ethnicity (%)	
Hispanic	35 (67%)
Black	15 (29%)
White	2 (4%)
Comorbidities	
Hypertension	27 (52%)
Diabetes Mellitus	16 (31%)
Coronary Artery Disease	7 (13%)
Chronic Kidney Disease	4 (8%)
Lung Disease (eg, COPD)	8 (15%)
No chronic disease	19 (36%)
COVID symptoms (%)	
Cough	33 (64%)
Shortness of breath	32 (62%)
Fever	31 (60%)
Diarrhea	13 (25%)
Chest Pain	10 (19%)
No COVID symptoms	11 (21%)
Oxygen Support Required (%)	
None	20 (38%)
Nasal Canula	29 (56%)
Non-Invasive Mechanical Ventilation	2 (4%)
Intubation	1 (2%)
Symptom duration prior to baseline collection Mean (range)	7 days (1 – 23 days)
Days between in-hospital NP swab PCR and baseline collection: mean (range)	2 days (0 – 10 days)
Number of follow-up time-points per participant: mean (range)	1.5 (0 – 10)
Participants with negative NP swab PCR collected in clinical follow-up during hospitalization	19 (38%)

388

Collected: 116 sample sets from 70 subjects

- 70 Baseline sample sets
- 46 Follow-up sample sets


Excluded: 14 sample sets with incomplete samples (no saliva, nasal swab, or oral swab)

18 Sample sets with all negative samples


Included in sample comparison analysis:

84 sample sets from 52 subjects

- 51 Baseline sample sets
- 33 Follow-up sample sets



% Positive



Cycle threshold (Ct)

